Brief: Orchard Therapeutics Announces Acceptance Of Biologics License Application For Otl-200 In Mld, Receives Priority Review
18/09/2023 12:04
Sept 18 (Reuters) - Orchard Therapeutics PLC OT10y.F :
* ORCHARD THERAPEUTICS ANNOUNCES ACCEPTANCE OF BIOLOGICS
LICENSE
APPLICATION FOR OTL-200 IN MLD AND RECEIVES PRIORITY REVIEW
* ORCHARD THERAPEUTICS PLC - AGENCY HAS SET A PRESCRIPTION
DRUG
USER FEE ACT (PDUFA) GOAL DATE OF MARCH 18, 2024
Source text for Eikon: ID:nGNX9qzJTk
Further company coverage: OT10y.F
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Orchard Therapeutics
See all newsBrief: Orchard Therapeutics Says Court Of Justice Of England & Wales Sanctioned Scheme Of Arrangement Providing For Acquisition Of Co By Kyowa Kirin Co's Unit
Brief: Orchard Therapeutics Receives U.S. FDA Fast Track Designation For OTL-203 In MPS-IH
Brief: Orchard Therapeutics Says U.S. FDA Advised Co It Does Not Intend To Schedule Advisory Committee Meeting
Orchard Therapeutics rises on buyout deal by Japanese drugmaker
Kyowa Kirin to acquire Orchard Therapeutics for $478 mln